Stay updated with breaking news from Phil Pang. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
– Prior data from the Phase 2 SOLSTICE trial in chronic hepatitis delta participants demonstrated that after only 12 weeks of combination therapy, 100% of participants had HDV RNA less than the...
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Executive Vice President, and Chief Medical Officer, Phil Pang, M.D., Ph.D., has decided to leave the company at the end of March 2024 to spend more time with his family. The Company has initiated a search for a successor. “Phil has served as a formidable leader at Vir, where he played a major part in the development of sotrovimab during the peak of the COVID-19 pandemic. With his background in infectious
Vir Biotechnology, Inc. today announced that Executive Vice President, and Chief Medical Officer, Phil Pang, M.D., Ph.D., has decided to leave the company at the end of March 2024 to spend more time...
Operator: Hello, and welcome to Vir Biotechnology's Third Quarter 2023 Financial Results and Business Update Call. As a reminder, this conference call is being recorded.